These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 26590712)

  • 1. Targeting Mitosis in Cancer: Emerging Strategies.
    Dominguez-Brauer C; Thu KL; Mason JM; Blaser H; Bray MR; Mak TW
    Mol Cell; 2015 Nov; 60(4):524-36. PubMed ID: 26590712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others.
    Warner SL; Gray PJ; Von Hoff DD
    Semin Oncol; 2006 Aug; 33(4):436-48. PubMed ID: 16890798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WEE1 inhibition and genomic instability in cancer.
    Vriend LE; De Witt Hamer PC; Van Noorden CJ; Würdinger T
    Biochim Biophys Acta; 2013 Dec; 1836(2):227-35. PubMed ID: 23727417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.
    Thu KL; Silvester J; Elliott MJ; Ba-Alawi W; Duncan MH; Elia AC; Mer AS; Smirnov P; Safikhani Z; Haibe-Kains B; Mak TW; Cescon DW
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1570-E1577. PubMed ID: 29378962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase.
    Colombo R; Caldarelli M; Mennecozzi M; Giorgini ML; Sola F; Cappella P; Perrera C; Depaolini SR; Rusconi L; Cucchi U; Avanzi N; Bertrand JA; Bossi RT; Pesenti E; Galvani A; Isacchi A; Colotta F; Donati D; Moll J
    Cancer Res; 2010 Dec; 70(24):10255-64. PubMed ID: 21159646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the mitotic regulatory network identifies highly efficient anti-cancer drug combinations.
    Wu Y; Zhuo X; Dai Z; Guo X; Wang Y; Zhang C; Lai L
    Mol Biosyst; 2015 Feb; 11(2):497-505. PubMed ID: 25418836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the cell cycle in breast cancer: towards the next phase.
    Thu KL; Soria-Bretones I; Mak TW; Cescon DW
    Cell Cycle; 2018; 17(15):1871-1885. PubMed ID: 30078354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PLK1 inhibitors: setting the mitotic death trap.
    Plyte S; Musacchio A
    Curr Biol; 2007 Apr; 17(8):R280-3. PubMed ID: 17437704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
    Sugimoto Y; Sawant DB; Fisk HA; Mao L; Li C; Chettiar S; Li PK; Darby MV; Brueggemeier RW
    Bioorg Med Chem; 2017 Apr; 25(7):2156-2166. PubMed ID: 28259529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-mitotic therapies in cancer.
    Tischer J; Gergely F
    J Cell Biol; 2019 Jan; 218(1):10-11. PubMed ID: 30545842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines.
    Libouban MAA; de Roos JADM; Uitdehaag JCM; Willemsen-Seegers N; Mainardi S; Dylus J; de Man J; Tops B; Meijerink JPP; Storchová Z; Buijsman RC; Medema RH; Zaman GJR
    Oncotarget; 2017 Jun; 8(24):38309-38325. PubMed ID: 28415765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of Aurora kinase inhibitors in cancer.
    Naruganahalli KS; Lakshmanan M; Dastidar SG; Ray A
    Curr Opin Investig Drugs; 2006 Dec; 7(12):1044-51. PubMed ID: 17209521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aurora kinase A inhibitors: promising agents in antitumoral therapy.
    Malumbres M; Pérez de Castro I
    Expert Opin Ther Targets; 2014 Dec; 18(12):1377-93. PubMed ID: 25200357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division.
    Maia ARR; Linder S; Song JY; Vaarting C; Boon U; Pritchard CEJ; Velds A; Huijbers IJ; van Tellingen O; Jonkers J; Medema RH
    Br J Cancer; 2018 Jun; 118(12):1586-1595. PubMed ID: 29736010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases.
    Marxer M; Ma HT; Man WY; Poon RY
    Oncogene; 2014 Jul; 33(27):3550-60. PubMed ID: 23955083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in mitotic inhibitors for cancer treatment.
    Jiang N; Wang X; Yang Y; Dai W
    Mini Rev Med Chem; 2006 Aug; 6(8):885-95. PubMed ID: 16918495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aurora kinases: new targets for cancer therapy.
    Carvajal RD; Tse A; Schwartz GK
    Clin Cancer Res; 2006 Dec; 12(23):6869-75. PubMed ID: 17145803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity.
    Uitdehaag JCM; de Man J; Willemsen-Seegers N; Prinsen MBW; Libouban MAA; Sterrenburg JG; de Wit JJP; de Vetter JRF; de Roos JADM; Buijsman RC; Zaman GJR
    J Mol Biol; 2017 Jul; 429(14):2211-2230. PubMed ID: 28539250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-mitotic agents: Are they emerging molecules for cancer treatment?
    Penna LS; Henriques JAP; Bonatto D
    Pharmacol Ther; 2017 May; 173():67-82. PubMed ID: 28174095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors.
    Pitts TM; Davis SL; Eckhardt SG; Bradshaw-Pierce EL
    Pharmacol Ther; 2014 May; 142(2):258-69. PubMed ID: 24362082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.